Amphastar Pharmaceuticals (AMPH) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Amphastar Pharmaceuticals is expected to report Q3 2026 results on November 5 after the market closes, with analysts forecasting $0.864 EPS and $197.52 million in revenue.
• The company exceeded expectations in its latest quarter, reporting $0.91 EPS versus a $0.62 consensus estimate and revenue of $183.90 million versus $179.92 million expected.
• Despite a recent 3% share-price gain, analyst sentiment remains cautious: seven analysts rate the stock Hold and one rates it Sell, resulting in a consensus “Reduce” rating and an average price target of $22.50.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Amphastar Pharmaceuticals to announce earnings of $0.8640 per share and revenue of $197.52 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, analysts expect Amphastar Pharmaceuticals to post $2.43 EPS for the current fiscal year and $2.55 EPS for the next fiscal year.

Amphastar Pharmaceuticals Trading Up 3.0%

Shares of AMPH opened at $26.33 on Thursday. The stock has a market capitalization of $1.12 billion, a P/E ratio of 15.58, a PEG ratio of 4.84 and a beta of 0.90. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $29.52. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The firm has a fifty day simple moving average of $24.54 and a two-hundred day simple moving average of $22.32.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the transaction, the executive vice president owned 169,203 shares in the company, valued at approximately $4,050,719.82. This represents a 5.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 7,973 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total transaction of $161,851.90. Following the transaction, the director owned 29,625 shares in the company, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 33,479 shares of company stock worth $763,922. Corporate insiders own 29.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMPH. Wall Street Zen downgraded shares of Amphastar Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 24th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating on the stock in a research report on Friday, August 7th. Weiss Ratings upgraded Amphastar Pharmaceuticals from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, October 16th. Barclays increased their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company increased their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $22.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.